Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases

NCT05598684 is registered in ClinicalTrials.gov with Fresenius Kabi, France as lead sponsor.

NCT NCT05598684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05598684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
Lead sponsor
Fresenius Kabi, France
Phase
Observational
Overall status
Unknown status
Start date
November 24, 2022
Completion date
December 30, 2025
Enrollment
600 (estimated)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, crohn disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis